Harvard Bioscience
HBIO
64 hedge funds and large institutions have $56.4M invested in Harvard Bioscience in 2020 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 21 increasing their positions, 25 reducing their positions, and 8 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
0.07% more ownership
Funds ownership: 6.31% → 6.38% (+0.07%)
6% less funds holding
Funds holding: 68 → 64 (-4)
16% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 25
23% less capital invested
Capital invested by funds: $73.2M → $56.4M (-$16.9M)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
Harvey Partners
Tarrytown,
New York
|
+$1.89M |
| 2 |
ECM
Engine Capital Management
New York
|
+$1.68M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.47M |
| 4 |
Renaissance Technologies
New York
|
+$382K |
| 5 |
GC
Globeflex Capital
San Diego,
California
|
+$218K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$1.06M |
| 2 |
FM
Fondren Management
Houston,
Texas
|
-$794K |
| 3 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$743K |
| 4 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
-$543K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$434K |
HBIO Hedge Fund Activity: Q1 2020 in Review
64 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q1 2020, worth a combined $56.4M — down 23% from $73.2M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of HBIO and 5 opened new positions — a net loss of 3 holders — while 25 trimmed existing stakes and 21 added.
The largest buyer was Harvey Partners, adding an estimated $1.89M. The largest seller was Kennedy Capital Management, cutting an estimated $1.06M.
- 64 institutional investors held Harvard Bioscience (HBIO) as of Q1 2020, down from 68 in Q4 2019.
- Funds reported $56.4M of Harvard Bioscience stock for Q1 2020, down 23% quarter-over-quarter.
- 5 funds opened new Harvard Bioscience positions in Q1 2020 and 8 closed out, a net change of -3 holders.
- The largest Harvard Bioscience buyer in Q1 2020 was Harvey Partners, an estimated $1.89M added.
- The largest Harvard Bioscience seller in Q1 2020 was Kennedy Capital Management, an estimated $1.06M sold.
Based on aggregated 13F filings for Q1 2020.